From discovery to durable value: Why advanced therapies need integrated planning across development, investment, evidence generation, and access

Download our white paper: From discovery to durable value: Why advanced therapies need integrated planning across development, investment, evidence generation, and access.

Advanced therapies address unmet medical needs where traditional modalities cannot, but they continue to face a unique set of obstacles to achieving value in the marketplace. In this white paper we explore:

• Five key considerations in the current advanced therapy landscape
• Why early commercial and investment planning matter
• Integrated models for advanced therapy readiness
• Building the next phase of advanced therapy success

If you are developing an advanced therapy, Uniphar is not your competition; we are your partner. Uniphar’s expert staff have decades of experience with advanced therapy sponsors and their regulatory interactions. They have built and commissioned manufacturing facilities delivering advanced therapy commercial product and have partnered on some of the most successful advanced therapy commercialization.

With expertise and capabilities spanning regulatory, manufacturing, clinical development, expanded access, medical, specialist logistics, access strategy, commericalization and patient care solutions, coupled with our global reach, Uniphar is helping sponsors integrate decisions that are too often made in isolation. For advanced therapies, this coordination makes the difference between a program that is clinically promising and one that has a future on the market.